Asgard Therapeutics AB, a private biotech company which originate from Lund University’s Cell Reprogramming and Immunity lab, led by the WCMM Fellow Professor Filipe Pereira, has announced the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden. Filipe Pereira is Asgard’s Co-Founder and Head of Innovation.
The company is developing a paradigm-shifting cancer immunotherapy approach, based on its proprietary TrojanDC technology, to reinstate cancer immunogenicity. TrojanDC is a gene therapy that reprograms cancer cells into type-1 conventional dendritic cells, allowing the presentation of their own antigens to the immune system, thereby eliciting potent anti-cancer immune responses. Designed as an off-the-shelf gene therapy, TrojanDC induces a personalized immune response, and overcomes many of the logistic and manufacturing hurdles of conventional cell-based therapies.